Similarly, the risk of pancreatic cancer, which was also hypothesized to be associated with GLP-1 medication, did not show any significant increase, with an OR of 0.25 (95% CI: 0.03–2.24). The gene discussed is GLP1R; the disease is familial pancreatic carcinoma.